Can-Fite BioPharma Ltd. (CANF)
CANF Price and Sentiment
CANF Latest news
Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
2021-10-26 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 09:25PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis" authored by Can-Fite's CEO Dr. Pnina Fishman.
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatt
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
2021-10-05 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
2021-09-17 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
2021-09-02 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
2021-08-26 12:48Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
2021-08-26 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
Can-Fite Announces $10.0 Million Registered Direct Offering
2021-08-12 08:00PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 5,000,000 of the Company's American Depositary Shares (ADSs) (or